Hormone Replacement Therapy (HRT) has become one of the most consistently requested services at medical spas, wellness clinics, and integrative health practices across the country. Patients experiencing the effects of age-related hormonal decline — diminished energy, weight gain, reduced libido, mood changes, and loss of lean muscle — are actively seeking providers who can help them address the root cause rather than simply manage individual symptoms.
For medical providers considering adding HRT to their service offerings, the opportunity is significant. But building a successful, sustainable HRT program requires more than simply sourcing a product. It demands a structured clinical approach, clear patient eligibility criteria, a compliant supply chain, and a working knowledge of the regulatory environment.
This guide is written specifically for licensed healthcare providers — physicians, nurse practitioners, physician assistants, and clinic operators — who are evaluating or actively building an HRT program. It covers the clinical fundamentals, patient assessment, protocol considerations, and what to look for when selecting a pharmaceutical supplier.
What Is Hormone Replacement Therapy?
Hormone Replacement Therapy refers to the clinical use of exogenous hormones to restore or optimize levels that have declined due to aging, medical conditions, or surgical intervention. In the weight loss and wellness clinic context, HRT most commonly involves testosterone in male patients and testosterone, estrogen, or progesterone (or combinations thereof) in female patients.
The underlying premise is straightforward: hormones regulate a wide range of physiological processes — metabolism, body composition, mood, cognitive function, sexual health, and cardiovascular markers, among others. When hormone levels fall below optimal ranges, patients often experience a constellation of symptoms that significantly affect quality of life. HRT aims to restore those levels to a physiologically appropriate range under physician supervision.
It is important to distinguish between the clinical use of HRT for diagnosed hormone deficiency and the broader concept of “hormone optimization” sometimes marketed in the wellness space. Providers operating within standard medical practice focus on diagnosed deficiency with documented lab values, individualized prescribing, and ongoing monitoring — not blanket supplementation.
Types of HRT Commonly Offered in Clinical Settings
Testosterone Replacement Therapy (TRT)
Testosterone Replacement Therapy is primarily indicated for male patients with clinically and biochemically confirmed hypogonadism — low testosterone levels accompanied by relevant symptoms. It is also used in female patients at lower doses for specific indications including low libido and hormonal balance support, typically under the care of an experienced HRT provider.
Common administration routes for testosterone include:
- Intramuscular or subcutaneous injections (testosterone cypionate or enanthate)
- Topical gels and creams
- Subcutaneous pellet implants
- Transdermal patches
Injectable testosterone remains one of the most common forms used in clinic-based TRT programs due to its predictable pharmacokinetics, relative cost-effectiveness, and the ability to fine-tune dosing based on laboratory monitoring.
Estrogen and Progesterone Therapy
In female patients, HRT most commonly addresses the hormonal changes associated with perimenopause and menopause — declining estrogen and progesterone levels that produce symptoms including hot flashes, sleep disruption, mood instability, vaginal atrophy, and accelerated bone density loss.
Estrogen therapy may be administered as:
- Oral preparations
- Transdermal patches or gels
- Topical creams or vaginal formulations
- Subcutaneous pellets
Progesterone or progestin is typically co-administered in patients with an intact uterus to offset estrogen’s effects on the uterine lining. Bioidentical progesterone (chemically identical to endogenous progesterone) is available through compounding pharmacies and is frequently requested by patients and providers seeking formulations not available in commercially produced quantities or delivery forms.
DHEA and Adjunctive Hormones
Some HRT programs incorporate dehydroepiandrosterone (DHEA), a precursor hormone produced by the adrenal glands that declines significantly with age. DHEA supplementation is sometimes used adjunctively in both male and female patients, though providers should be aware that the evidence base for DHEA supplementation is more limited than for testosterone or estrogen therapy, and claims should be framed accordingly.
Patient Selection and Eligibility
A well-designed HRT program begins with rigorous patient selection. Appropriate patient identification protects your patients, reduces liability exposure, and forms the clinical foundation on which outcomes — and your program’s reputation — are built.
Baseline Laboratory Assessment
No HRT program should initiate therapy without documented baseline laboratory values. A standard pre-treatment panel for male patients typically includes:
- Total and free testosterone
- Sex hormone-binding globulin (SHBG)
- Luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
- Estradiol
- Complete blood count (CBC) — specifically hematocrit, given TRT’s effects on red blood cell production
- Comprehensive metabolic panel
- Lipid panel
- PSA (prostate-specific antigen) in male patients over 40
- Thyroid function (TSH)
For female patients, the panel is adjusted to include estradiol, progesterone, FSH, LH, and DHEA-S, among other markers appropriate to the patient’s age and symptom profile.
Thorough baseline labs serve multiple purposes: they confirm the clinical indication for therapy, establish a reference point for monitoring, identify contraindications, and provide objective data that demonstrates patient progress over time.
Contraindications
Providers must screen patients for contraindications prior to initiating any hormone therapy. Absolute or relative contraindications vary by hormone type but generally include:
- Active or history of hormone-sensitive cancers (breast, prostate, uterine)
- Untreated or poorly controlled cardiovascular disease
- Elevated hematocrit or polycythemia (for TRT)
- Active thromboembolic disease or high DVT/PE risk
- Uncontrolled hypertension
- Severe liver disease
- Pregnancy or planned pregnancy
A thorough intake history and physical examination, combined with baseline labs, should inform every prescribing decision. Providers are encouraged to maintain clinical documentation that clearly supports the therapeutic rationale for each patient.
Building Your HRT Protocol
A standardized protocol gives your program consistency, reduces variability in outcomes, and demonstrates clinical rigor to patients and regulators alike. The following framework reflects common practice in medically supervised HRT programs and should be adapted by your clinical team based on your patient population, scope of practice, and applicable state regulations.
Initial Consultation and Informed Consent
Before initiating any hormone therapy, patients should complete a thorough intake process that includes a symptom questionnaire, medical history review, and discussion of the risks, benefits, alternatives, and unknowns of the proposed treatment. Written informed consent should be obtained and retained in the patient’s chart.
Informed consent for HRT should acknowledge, at minimum:
- That therapy will be tailored to the individual based on lab values and symptoms
- The known risks associated with the specific hormones being prescribed
- That ongoing monitoring is required and is a condition of continued treatment
- That compounded hormone preparations, where applicable, are not FDA-approved and have not been individually evaluated by the FDA for safety, efficacy, or quality
- That the patient understands the difference between FDA-approved hormone products and compounded alternatives
Dosing and Titration
HRT dosing is highly individualized. Starting doses are typically conservative, with titration guided by follow-up laboratory values and symptom response. For testosterone therapy in male patients, a common starting point for injectable cypionate is in a range determined by the prescribing physician based on the patient’s baseline labs and clinical presentation, with adjustments made at regular intervals based on follow-up values.
The goal is not to maximize hormone levels but to restore them to a range that resolves symptoms while remaining within physiologically appropriate parameters. Providers should resist patient pressure to escalate doses beyond what labs and clinical assessment support.
Ongoing Monitoring
Regular follow-up is non-negotiable in any HRT program. Patients on TRT should have labs repeated at 6–8 weeks after initiation or any dose change, then every 3–6 months once stabilized. Female hormone therapy patients require similarly structured monitoring, with attention to symptom response, lab values, and any new or changing health conditions.
Monitoring intervals and parameters should be documented in your clinical protocol and communicated clearly to patients as a condition of program participation.
The Regulatory Framework for HRT Products
Medical providers offering HRT have access to both FDA-approved hormone products and compounded hormone preparations. Understanding the distinction — and the regulatory obligations each carries — is essential for operating a compliant program.
FDA-Approved Hormone Products
A range of FDA-approved testosterone, estrogen, and progesterone products are commercially available in standardized formulations and doses. These products have been evaluated by the FDA for safety, efficacy, and manufacturing quality. For patients whose clinical needs can be met by a commercially available product, prescribing an FDA-approved formulation is generally the appropriate starting point.
Compounded Hormone Preparations
Compounded hormone preparations are prepared by state-licensed 503A compounding pharmacies on a patient-specific, prescription basis. Compounding allows for customized dosing, alternative delivery routes, or formulations not commercially available — addressing genuine clinical needs that FDA-approved products may not meet for every individual patient.
Regulatory Note for Providers
Compounded hormone preparations are not FDA-approved medications. They have not been individually evaluated by the FDA for safety, effectiveness, or quality. Compounding is only lawful when performed by a state-licensed 503A pharmacy pursuant to a valid, patient-specific prescription from a licensed prescriber. Providers should not prescribe compounded hormones without individualized clinical justification for each patient.
Providers are strongly encouraged to consult with a qualified healthcare regulatory attorney regarding their obligations under applicable federal and state compounding laws before establishing or expanding any hormone therapy program.
What to Look for in an HRT Pharmaceutical Supplier
Your pharmaceutical supplier is a direct extension of your clinical program. The quality, consistency, and compliance posture of the products you source reflects on your practice and your patients’ outcomes. When evaluating a supplier for HRT products, the following criteria should be non-negotiable:
- State licensure and accreditation — confirm the pharmacy holds current licensure in your state and, where applicable, PCAB accreditation
- Certificate of Analysis (COA) for every lot — confirming identity, potency, purity, and sterility testing
- Active pharmaceutical ingredients sourced from FDA-registered manufacturers
- Documented sterility testing for all injectable preparations
- Clear labeling including lot number, beyond-use date, and required regulatory language
- Responsive customer service and a dedicated point of contact for your practice
- Transparent compounding processes and willingness to answer compliance questions
Providers should also ensure that their supplier relationship is structured appropriately — with patient-specific prescriptions transmitted for each compounded preparation, and records maintained in accordance with applicable state and federal requirements.
Adding HRT to Your Practice: Getting Started
For providers ready to add HRT to their service offerings, the following steps provide a practical starting framework:
- Define your scope — determine which hormone therapies you will offer based on your clinical training, staff capabilities, and patient population
- Build your protocol — develop standardized intake, assessment, dosing, and monitoring workflows before seeing your first HRT patient
- Establish your lab relationships — identify a reliable laboratory partner for baseline and follow-up testing
- Select a compliant pharmaceutical supplier — apply the criteria above and verify licensing before placing any orders
- Train your team — ensure all clinical and administrative staff understand the program workflow, documentation requirements, and patient communication standards
- Review your informed consent documents — have them reviewed by legal counsel familiar with hormone therapy and compounding regulations in your state
National Medical Resources, Inc. (NMR Meds) supports licensed medical providers with a range of pharmaceutical products for wellness and hormone therapy programs. To learn more about establishing a provider account, visit nmrmeds.com or contact our team at info@nmrmeds.com.
MEDICAL & LEGAL DISCLAIMER
The information contained in this article is intended for licensed healthcare providers and qualified medical professionals only. It is provided for general informational and educational purposes and does not constitute medical advice, clinical guidance, or a substitute for the independent professional judgment of a licensed physician or other qualified healthcare provider.
Nothing in this article should be construed as a recommendation to diagnose, treat, cure, or prevent any disease or medical condition, nor as guidance on prescribing or administering any pharmaceutical compound to any specific patient. All clinical decisions regarding patient eligibility, dosing, monitoring, and treatment should be made by a licensed healthcare provider based on the individual patient’s clinical presentation, medical history, and applicable standard of care.
COMPOUNDED MEDICATION DISCLOSURE:
Compounded medications, including compounded semaglutide and tirzepatide, are not FDA-approved drugs and have not been evaluated by the U.S. Food and Drug Administration for safety, effectiveness, or quality. Compounded drugs are not generic versions of, and are not the same as or equivalent to, FDA-approved products such as Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. Compounded semaglutide and tirzepatide may only be dispensed pursuant to a valid, patient-specific prescription issued by a licensed prescriber. Nothing in this article constitutes a claim that any compounded product is clinically proven, has been evaluated in clinical trials, or produces the same results as any FDA-approved drug.
The regulatory landscape governing compounded medications is subject to change. Information provided in this article reflects publicly available guidance as of the publication date and may not reflect the most current regulatory requirements. Readers are strongly encouraged to consult with a qualified healthcare regulatory attorney and to monitor updates from the U.S. Food and Drug Administration (FDA) and applicable state pharmacy boards before initiating or modifying any compounding or dispensing program.
National Medical Resources, Inc. (NMR Meds) is a distributor of medical and wellness products to licensed healthcare providers. NMR Meds does not provide medical advice, clinical consultation, or legal guidance. References to specific products, dosing schedules, or clinical protocols in this article are for informational and educational purposes only and do not constitute an endorsement of any specific treatment approach.
© 2026 National Medical Resources, Inc. All rights reserved. This content is intended for licensed healthcare professionals and may not be reproduced or redistributed without written permission.